Nabumetone Granules

This product is a non-acidic non-steroidal anti-inflammatory drug and a prodrug. It is rapidly metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA) in the liver and has antipyretic, analgesic and anti-inflammatory effects. 1. The anti-inflammatory, analgesic and antipyretic effects are related to the fact that the active metabolites of cabutimetone inhibit the synthesis of prostaglandins in inflammatory tissues; 2. Little effect on gastric mucosa: This product is a non-acidic, non-ionic prodrug, which has no obvious local direct effect on gastric mucosa during absorption; at the same time, this product has little inhibitory effect on the physiological cyclooxygenase of gastric mucosa. Therefore, the incidence of gastrointestinal mucosal erosion and bleeding caused by this product is low; 3. No effect on bleeding and coagulation: This product has no effect on the platelet aggregation induced in vitro in blood samples of healthy volunteers. There are no significant changes in bleeding time and coagulation tests.

Nabumetone

White or off-white crystalline powder, odorless and tasteless.

It is suitable for osteoarthritis, rheumatoid arthritis and similar symptoms that require anti-inflammatory treatment. It is used for various acute and chronic arthritis, sports soft tissue injuries, postoperative pain, toothache, and dysmenorrhea.

1. The usual dosage for adults is 1.0g orally, once a day. The maximum daily dosage is 2g, divided into two doses. Adults weighing less than 50kg can start with 0.5g per day. Gradually increase the dosage to the effective dose; 2. The dosage for children has not yet been established.

1. Gastrointestinal tract: nausea, vomiting, indigestion, diarrhea, abdominal pain and constipation, about 1% to 3%. Upper gastrointestinal bleeding, about 0.7%. In the cases of this product, the incidence of ulcers in the short-term treatment group (6 weeks to 6 months) and the long-term treatment group (8 years) were 0.1% and 0.95%, respectively. The incidence of diarrhea increased with daily oral administration of 2g of nabumetone; 2. Nervous system: manifestations include headache, dizziness, tinnitus, sweating, insomnia, drowsiness, tension and dreaminess, with an incidence of less than 1.5%; 3. Skin: rash and itching, about 2.1%, edema, about 1.1% 4. Rare or occasional adverse reactions include jaundice, abnormal liver function, anxiety, depression, paresthesia, tremor, dizziness, bullous rash, urticaria, dyspnea, asthma, allergic pneumonia, proteinuria, hematuria and vascular neurosis

It is contraindicated for patients with active peptic ulcer or bleeding, severe liver function abnormalities, and allergies to this product and other non-steroidal anti-inflammatory drugs.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. The combined use of aluminum hydroxide gel, aspirin or acetaminophen does not affect the absorption rate of this product. However, it is generally not recommended to use two or more non-steroidal anti-inflammatory drugs at the same time; 2. There is no interaction between this product and the anticoagulant warfarin in healthy volunteers. However, there is no data on the combined use of these two drugs in patients; 3. The dosage should be appropriately reduced when this product is used in combination with acetyl anticonvulsants and sulfonylurea hypoglycemic drugs.

Keep away from light and store in a sealed container.

0.5 g

30 months

Fuan Pharmaceutical Group Hubei Renmin Pharmaceutical Co., Ltd.

• Founded in:

  2001-11-13

• Address:

  No. 1 Qijiashante, Baiquan, Dongxihu District, Wuhan

• Tax NO.:

  91420112732707909X

• Registered Funds:

  111.99 million yuan

• Website:

  Log in to view

• Email:

  Log in to view